Quarterly report · Q2
6523.TEDINET S100PICM
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥170.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥89.1bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.1bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥85.1bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥13.5bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥7.9bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥9.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.0bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥8.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥15.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.6bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥596.3bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.2bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥446.9bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥149.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥124.1bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥148.3bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥123.5bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥73.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥59.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥20.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥8.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥9.61 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.6 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.67 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥9.52 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥65.98 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥125.01 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥38.42 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.9% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 21.7% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥9.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥55.4bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥49.3bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥64.8bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥169.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥20.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥8.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥53.7bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥10.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥66.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.8bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥164.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥22.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 976
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -9442000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 10540000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 134000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 7280000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 3395000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember | 5172000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember | 5409000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 3855000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReportableSegmentsMember | 14436000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReconcilingItemsMember | 372000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration | 14809000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember | 139000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 4000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReportableSegmentsMember | 143000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReconcilingItemsMember | 114000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 257000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第10期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | PHC Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 宮﨑 正次 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区西新橋二丁目38番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） フレデリック・ライデンバック | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区西新橋二丁目38番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） フレデリック・ライデンバック | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E36976 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 65230 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | PHC Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |